1. Medtech Insight
  2. >>Business

US Sales Of Sinclair Pharma's Silhouette InstaLift-Off

 
• By Catherine Longworth

Aesthetics company Sinclair Pharma has reported headline growth of 51% in 2016 due to strong unexpected interest for its Silhouette Instalift product.

Aesthetics company Sinclair Pharma PLC sales are growing rapidly following the US launch of its facelift product Silhouette Instalift. The non-surgical "one-stitch" facelift is performed under local anaesthesia and involves inserting a series of threaded biodegradable cones into the face to gently tighten and lift the skin.

Instalift launched in August 2016 via Sinclair's distribution partner Thermigen, the aesthetics subsidiary of pharma group Almirall SA. Also see "Sinclair Pharma's Non-Surgical Facelift Gains Access To US Market...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.